These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 23739238)

  • 21. Should rituximab be administered before cyclophosphamide as a first-line steroid-sparing agent to young children with steroid-dependent nephrotic syndrome?
    Fujinaga S; Mizutani A
    Clin Exp Nephrol; 2020 Dec; 24(12):1187-1188. PubMed ID: 32728924
    [No Abstract]   [Full Text] [Related]  

  • 22. Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children.
    Ravani P; Bonanni A; Rossi R; Caridi G; Ghiggeri GM
    Clin J Am Soc Nephrol; 2016 Apr; 11(4):710-20. PubMed ID: 26585985
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison of a standard-dose prednisone regimen and mycophenolate mofetil combined with a lower prednisone dose in Chinese adults with idiopathic nephrotic syndrome who were carriers of hepatitis B surface antigen: a prospective cohort study.
    Li X; Tian J; Wu J; He Q; Li H; Han F; Li Q; Chen Y; Ni Q; Chen J
    Clin Ther; 2009 Apr; 31(4):741-50. PubMed ID: 19446147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triple immunosuppressive therapy in steroid-resistant nephrotic syndrome children with tacrolimus resistance or tacrolimus sensitivity but frequently relapsing.
    Wu B; Mao J; Shen H; Fu H; Wang J; Liu A; Gu W; Shu Q; Du L
    Nephrology (Carlton); 2015 Jan; 20(1):18-24. PubMed ID: 25312783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized clinical trial to compare efficacy and safety of repeated courses of rituximab to single-course rituximab followed by maintenance mycophenolate-mofetil in children with steroid dependent nephrotic syndrome.
    Basu B; Preussler S; Sander A; Mahapatra TKS; Schaefer F
    BMC Nephrol; 2020 Nov; 21(1):520. PubMed ID: 33256621
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
    Vivarelli M; Colucci M; Bonanni A; Verzani M; Serafinelli J; Emma F; Ghiggeri G
    Pediatr Nephrol; 2017 Jan; 32(1):181-184. PubMed ID: 27687621
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome.
    Zhao M; Chen X; Chen Y; Liu Z; Liu Y; Lu F; Zhang Y; Wang H
    Nephrology (Carlton); 2003 Jun; 8(3):105-9. PubMed ID: 15012724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of rituximab treatment in children with primary glomerulonephritis.
    Zachwieja J; Silska M; Ostalska-Nowicka D; Soltysiak J; Lipkowska K; Blumczynski A; Musielak A
    J Nephrol; 2012; 25(6):1060-6. PubMed ID: 22322817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Initial treatment of idiopathic nephrotic syndrome in children: prednisone versus prednisone plus cyclosporine A: a prospective, randomized trial.
    Hoyer PF; Brodeh J
    J Am Soc Nephrol; 2006 Apr; 17(4):1151-7. PubMed ID: 16540560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prolonged Impairment of Immunological Memory After Anti-CD20 Treatment in Pediatric Idiopathic Nephrotic Syndrome.
    Colucci M; Carsetti R; Serafinelli J; Rocca S; Massella L; Gargiulo A; Lo Russo A; Capponi C; Cotugno N; Porzio O; Onetti Muda A; Palma P; Emma F; Vivarelli M
    Front Immunol; 2019; 10():1653. PubMed ID: 31379849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Multicenter survey of diagnostic and therapeutic status in Chinese childhood patients with steroid-sensitive, relaping/steroid-dependent nephrotic syndrome].
    Working Group For National Survey On Status Of Diagnosis And Treatment Of Childhood Renal Diseases
    Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):194-200. PubMed ID: 24824389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of rituximab in children with difficult-to-treat nephrotic syndrome.
    Sinha A; Bhatia D; Gulati A; Rawat M; Dinda AK; Hari P; Bagga A
    Nephrol Dial Transplant; 2015 Jan; 30(1):96-106. PubMed ID: 25121488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Difficult-to-treat idiopathic nephrotic syndrome: established drugs, open questions and future options.
    Kemper MJ; Valentin L; van Husen M
    Pediatr Nephrol; 2018 Oct; 33(10):1641-1649. PubMed ID: 28879428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Podocyte sphingomyelin phosphodiesterase acid-like 3b decreases among children with idiopathic nephrotic syndrome.
    Watanabe S; Hirono K; Aizawa T; Tsugawa K; Joh K; Imaizumi T; Tanaka H
    Clin Exp Nephrol; 2021 Jan; 25(1):44-51. PubMed ID: 32946006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.
    Webb H; Jaureguiberry G; Dufek S; Tullus K; Bockenhauer D
    Pediatr Nephrol; 2016 Apr; 31(4):589-94. PubMed ID: 26525199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy.
    Ramachandran R; Bharati J; Rao I; Kashif AW; Nada R; Minz R; Gupta KL; Kohli HS
    Nephrology (Carlton); 2019 Dec; 24(12):1241-1247. PubMed ID: 30586217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome.
    Ito S; Kamei K; Ogura M; Sato M; Fujimaru T; Ishikawa T; Udagawa T; Iijima K
    Pediatr Nephrol; 2011 Oct; 26(10):1823-8. PubMed ID: 21556716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment with tacrolimus and prednisolone is preferable to intravenous cyclophosphamide as the initial therapy for children with steroid-resistant nephrotic syndrome.
    Gulati A; Sinha A; Gupta A; Kanitkar M; Sreenivas V; Sharma J; Mantan M; Agarwal I; Dinda AK; Hari P; Bagga A
    Kidney Int; 2012 Nov; 82(10):1130-5. PubMed ID: 22763815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomised controlled trial comparing rituximab to mycophenolate mofetil in children and young adults with steroid-dependent idiopathic nephrotic syndrome: study protocol.
    Lugani F; Angeletti A; Ravani P; Vivarelli M; Colucci M; Caridi G; Verrina E; Emma F; Ghiggeri GM
    BMJ Open; 2021 Nov; 11(11):e052450. PubMed ID: 34845071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study.
    Ravani P; Lugani F; Pisani I; Bodria M; Piaggio G; Bartolomeo D; Prunotto M; Ghiggeri GM
    Pediatr Nephrol; 2020 Aug; 35(8):1437-1444. PubMed ID: 32232637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.